[New drugs for HIV infection].
Taéron
Corinne
C
D019380:Anti-HIV Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D000075202:Contraindications; D003510:Cyclohexanes / Q000627:therapeutic use; D000069454:Darunavir; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D015658:HIV Infections / Q000188:drug therapy* / Q000451:nursing; D006801:Humans; D000077592:Maraviroc; D009570:Nitriles; D009930:Organic Chemicals / Q000627:therapeutic use; D010353:Patient Education as Topic; D018579:Patient Selection; D011724:Pyridazines / Q000627:therapeutic use; D011743:Pyrimidines; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D013449:Sulfonamides / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
D019380:Anti-HIV Agents; D003510:Cyclohexanes; D009570:Nitriles; D009930:Organic Chemicals; D011724:Pyridazines; D011743:Pyrimidines; D011760:Pyrrolidinones; D013449:Sulfonamides; D014230:Triazoles; C451734:etravirine; D000068898:Raltegravir Potassium; D000077592:Maraviroc; D000069454:Darunavir